{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:04:23Z","timestamp":1792555463728,"version":"4.5.0"},"reference-count":182,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Radioimmunoconjugates consist of a monoclonal antibody (mAb) linked to a radionuclide. Radioimmunoconjugates as theranostics tools have been in development with success, particularly in hematological malignancies, leading to approval by the US Food and Drug Administration (FDA) for the treatment of non-Hodgkin\u2019s lymphoma. Radioimmunotherapy (RIT) allows for reduced toxicity compared to conventional radiation therapy and enhances the efficacy of mAbs. In addition, using radiolabeled mAbs with imaging methods provides critical information on the pharmacokinetics and pharmacodynamics of therapeutic agents with direct relevance to the optimization of the dose and dosing schedule, real-time antigen quantitation, antigen heterogeneity, and dynamic antigen changes. All of these parameters are critical in predicting treatment responses and identifying patients who are most likely to benefit from treatment. Historically, RITs have been less effective in solid tumors; however, several strategies are being investigated to improve their therapeutic index, including targeting patients with minimal disease burden; using pre-targeting strategies, newer radionuclides, and improved labeling techniques; and using combined modalities and locoregional application. This review provides an overview of the radiolabeled intact antibodies currently in clinical use and those in development.<\/jats:p>","DOI":"10.3390\/cancers14061454","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T12:58:36Z","timestamp":1647003516000},"page":"1454","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["Radiolabeled Antibodies for Cancer Imaging and Therapy"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3891-2489","authenticated-orcid":false,"given":"Sagun","family":"Parakh","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Heidelberg, VIC 3084, Australia"},{"name":"Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia"},{"name":"School of Cancer Medicine, La Trobe University, Heidelberg, VIC 3086, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze Ting","family":"Lee","sequence":"additional","affiliation":[{"name":"Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia"},{"name":"School of Cancer Medicine, La Trobe University, Heidelberg, VIC 3086, Australia"},{"name":"Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC 3084, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7319-8546","authenticated-orcid":false,"given":"Hui K.","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Heidelberg, VIC 3084, Australia"},{"name":"Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia"},{"name":"School of Cancer Medicine, La Trobe University, Heidelberg, VIC 3086, Australia"},{"name":"Department of Medicine, University of Melbourne, Heidelberg, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Scott","sequence":"additional","affiliation":[{"name":"Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia"},{"name":"School of Cancer Medicine, La Trobe University, Heidelberg, VIC 3086, Australia"},{"name":"Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC 3084, Australia"},{"name":"Department of Medicine, University of Melbourne, Heidelberg, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1517\/17425247.2016.1124854","article-title":"Antibody-mediated delivery of therapeutics for cancer therapy","volume":"13","author":"Parakh","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3389\/fimmu.2020.01155","article-title":"Targeted therapy with immunoconjugates for multiple myeloma","volume":"11","author":"Bruins","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/978-1-61779-974-7_38","article-title":"Radiolabeled antibodies for cancer imaging and therapy","volume":"907","author":"Barbet","year":"2012","journal-title":"Antib. Eng."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2967\/jnumed.115.167247","article-title":"Radioimmunotherapy: From current clinical success to future industrial breakthrough?","volume":"57","author":"Barbet","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Harsini, S., and Rezaei, N. (2020). Cancer imaging with radiolabeled monoclonal antibodies. Cancer Immunology, Springer.","DOI":"10.1007\/978-3-030-30845-2_32"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.7150\/thno.25575","article-title":"Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a","volume":"8","author":"Burvenich","year":"2018","journal-title":"Theranostics"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.radonc.2016.11.020","article-title":"PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer","volume":"122","author":"Even","year":"2017","journal-title":"Radiother. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2967\/jnumed.118.214726","article-title":"Immuno-PET imaging to assess target engagement: Experience from 89Zr-anti-HER3 mAb (GSK2849330) in patients with solid tumors","volume":"60","author":"McGeoch","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00259-019-04555-6","article-title":"[89Zr] Zr-cetuximab PET\/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer","volume":"47","author":"Elias","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2967\/jnumed.108.054312","article-title":"Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET","volume":"50","author":"Aerts","year":"2009","journal-title":"J. Nucl. Med."},{"key":"ref_11","first-page":"17","article-title":"Development and characterization of 89Zr-labeled panitumumab for immuno\u2013positron emission tomographic imaging of the epidermal growth factor receptor","volume":"12","author":"Chang","year":"2013","journal-title":"Mol. Imaging"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Nayak, T.K., Garmestani, K., Milenic, D.E., Baidoo, K.E., and Brechbiel, M.W. (2011). HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018198"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0305-7372(10)70012-8","article-title":"Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer","volume":"36","author":"Bencardino","year":"2010","journal-title":"Cancer Treat. Rev."},{"key":"ref_14","first-page":"195","article-title":"Dosimetry and first human experience with 89Zr-panitumumab","volume":"7","author":"Lindenberg","year":"2017","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_15","first-page":"688","article-title":"89Zr-nimotuzumab for potential clinical translation as an anti-EGFR immunoPET agent","volume":"58","author":"Chekol","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"30375","DOI":"10.1074\/jbc.M401218200","article-title":"Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor","volume":"279","author":"Johns","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1158\/0008-5472.CAN-11-3898","article-title":"Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy","volume":"72","author":"Gan","year":"2012","journal-title":"Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/sj.bjc.6602470","article-title":"Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR","volume":"92","author":"Panousis","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1073\/pnas.0611693104","article-title":"A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors","volume":"104","author":"Scott","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2967\/jnumed.120.253146","article-title":"A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806","volume":"62","author":"Gan","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2017.06.005","article-title":"Evolution of anti-HER2 therapies for cancer treatment","volume":"59","author":"Parakh","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1158\/1538-7445.AM2014-109","article-title":"PET imaging of 89Zr-labeled pertuzumab in HER2-positive breast cancer xenografts","volume":"74","author":"Marquez","year":"2014","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/CCO.0b013e32833f8c3a","article-title":"Molecular imaging of HER2-positive breast cancer-a step toward an individualized \u201cImage and Treat\u201d strategy","volume":"22","author":"Capala","year":"2010","journal-title":"Curr. Opin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/jlcr.3465","article-title":"Preparation and preclinical evaluation of 131I-trastuzumab for breast cancer","volume":"60","author":"Kameswaran","year":"2017","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1007\/s00259-017-3663-y","article-title":"Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer","volume":"44","author":"Jiang","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1021\/mp500323d","article-title":"Evaluation of 89Zr-pertuzumab in breast cancer xenografts","volume":"11","author":"Marquez","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/0008-5472.CAN-06-2363","article-title":"[177Lu] Pertuzumab: Experimental Therapy of HER-2\u2013Expressing Xenografts","volume":"67","author":"Persson","year":"2007","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/clpt.2010.12","article-title":"Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer","volume":"87","author":"Dijkers","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"974","DOI":"10.2967\/jnumed.108.060392","article-title":"Development and characterization of clinical-grade 89Zr-trastuzumab for HER2\/neu immunoPET imaging","volume":"50","author":"Dijkers","year":"2009","journal-title":"J. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/annonc\/mdv577","article-title":"Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): The ZEPHIR trial","volume":"27","author":"Gebhart","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1007\/s00259-018-4099-8","article-title":"89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up","volume":"45","author":"Bensch","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/RLU.0000000000001820","article-title":"89Zr-trastuzumab PET\/CT for detection of human epidermal growth factor receptor 2\u2013positive metastases in patients with human epidermal growth factor receptor 2\u2013negative primary breast cancer","volume":"42","author":"Ulaner","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2967\/jnumed.117.194555","article-title":"Pharmacokinetics, biodistribution, and radiation dosimetry for 89Zr-trastuzumab in patients with esophagogastric cancer","volume":"59","author":"Lewis","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2967\/jnumed.112.118612","article-title":"64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer","volume":"54","author":"Tamura","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2967\/jnumed.117.193888","article-title":"Tumor uptake of 64Cu-DOTA-trastuzumab in patients with metastatic breast cancer","volume":"59","author":"Mortimer","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13550-015-0082-6","article-title":"64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients","volume":"5","author":"Kurihara","year":"2015","journal-title":"EJNMMI Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ijc.30500","article-title":"Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients","volume":"140","author":"Bhusari","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"900","DOI":"10.2967\/jnumed.117.202010","article-title":"First-in-human human epidermal growth factor receptor 2\u2013targeted imaging using 89Zr-Pertuzumab PET\/CT: Dosimetry and clinical application in patients with breast cancer","volume":"59","author":"Ulaner","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1148\/radiol.2020192828","article-title":"Identification of HER2-positive metastases in patients with HER2-negative primary breast cancer by using HER2-targeted 89Zr-pertuzumab PET\/CT","volume":"296","author":"Ulaner","year":"2020","journal-title":"Radiology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"18898","DOI":"10.1038\/s41598-019-54824-5","article-title":"CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models","volume":"9","author":"Huizing","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"11402","DOI":"10.3390\/ijms140611402","article-title":"Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma","volume":"14","author":"Boerman","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00259-019-04358-9","article-title":"Lesion detection by [89Zr] Zr-DFO-girentuximab and [18F] FDG-PET\/CT in patients with newly diagnosed metastatic renal cell carcinoma","volume":"46","author":"Verhoeff","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1007\/s00259-021-05271-w","article-title":"Phase I study to assess safety, biodistribution and radiation dosimetry for 89Zr-girentuximab in patients with renal cell carcinoma","volume":"48","author":"Merkx","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.eururo.2018.04.026","article-title":"Positron emission tomography\/computed tomography with 89Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion","volume":"74","author":"Hekman","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2011.41.2445","article-title":"Positron emission tomography\/computed tomography identification of clear cell renal cell carcinoma: Results from the REDECT trial","volume":"31","author":"Divgi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1536012118801223","DOI":"10.1177\/1536012118801223","article-title":"Application of Immuno-PET in antibody\u2013drug conjugate development","volume":"17","author":"Carmon","year":"2018","journal-title":"Mol. Imaging"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40336-020-00379-9","article-title":"New insight and future perspective of mesothelin-targeted agents in nuclear medicine","volume":"8","author":"Conte","year":"2020","journal-title":"Clin. Transl. Imaging"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.nucmedbio.2011.05.003","article-title":"Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody","volume":"38","author":"Shin","year":"2011","journal-title":"Nucl. Med. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Montemagno, C., Cassim, S., Trichanh, D., Savary, C., Pouyssegur, J., Fagret, D., Broisat, A., and Ghezzi, C. (2019). 99mTc-A1 as a novel imaging agent targeting mesothelin-expressing pancreatic ductal adenocarcinoma. Cancers, 11.","DOI":"10.3390\/cancers11101531"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/1078-0432.CCR-15-1272","article-title":"ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody\u2013drug conjugate treatment","volume":"22","author":"Lamberts","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: An analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/0008-5472.CAN-14-3477","article-title":"Noninvasive imaging of tumor PD-L1 expression using radiolabeled anti\u2013PD-L1 antibodies","volume":"75","author":"Heskamp","year":"2015","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"10215","DOI":"10.18632\/oncotarget.7143","article-title":"A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors","volume":"7","author":"Chatterjee","year":"2016","journal-title":"Oncotarget"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.7150\/thno.15253","article-title":"High-resolution PET imaging with therapeutic antibody-based PD-1\/PD-L1 checkpoint tracers","volume":"6","author":"Hettich","year":"2016","journal-title":"Theranostics"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1021\/acs.bioconjchem.6b00348","article-title":"PD-L1 detection in tumors using [64Cu] atezolizumab with PET","volume":"27","author":"Lesniak","year":"2016","journal-title":"Bioconjugate Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2967\/jnumed.116.177857","article-title":"Preclinical pharmacokinetics and biodistribution studies of 89Zr-labeled pembrolizumab","volume":"58","author":"England","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00259-017-3803-4","article-title":"89Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer","volume":"45","author":"England","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"van der Veen, E.L., Giesen, D., Pot-de Jong, L., Jorritsma-Smit, A., De Vries, E.G., and Lub-de Hooge, M.N. (2020). 89Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs. J. Immunother. Cancer, 8.","DOI":"10.1136\/jitc-2020-000938"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.7150\/thno.24762","article-title":"Noninvasive imaging of the PD-1: PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy","volume":"8","author":"Broos","year":"2018","journal-title":"Theranostics"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","article-title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","volume":"24","author":"Bensch","year":"2018","journal-title":"Nat. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer","volume":"9","author":"Niemeijer","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S1470-2045(17)30379-0","article-title":"Targeted radionuclide therapy in combined-modality regimens","volume":"18","author":"Gill","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrclinonc.2011.160","article-title":"Clinical radioimmunotherapy\u2014the role of radiobiology","volume":"8","author":"Pouget","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc3925","article-title":"Radioimmunotherapy of human tumours","volume":"15","author":"Larson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.addr.2008.04.007","article-title":"Alpha-particles for targeted therapy","volume":"60","author":"Sgouros","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Huang, G. (2019). Nuclear Medicine in Oncology, Springer.","DOI":"10.1007\/978-981-13-7458-6"},{"key":"ref_67","first-page":"4336","article-title":"Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial","volume":"99","author":"Wiseman","year":"2002","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan","volume":"109","author":"Witzig","year":"2007","journal-title":"Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1002\/cncr.27418","article-title":"A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma","volume":"118","author":"Shimoni","year":"2012","journal-title":"Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","article-title":"90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: Updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90\u2013ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3816\/CLM.2009.n.044","article-title":"Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: A phase II trial of the Sarah Cannon Oncology Research Consortium","volume":"9","author":"Hainsworth","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1158\/1078-0432.CCR-08-0529","article-title":"Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma","volume":"14","author":"Jacobs","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/10428194.2013.790544","article-title":"Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate-and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: A multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group","volume":"55","author":"Provencio","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","article-title":"Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin\u2019s lymphomas","volume":"23","author":"Fisher","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1200\/JCO.2009.27.8325","article-title":"Cyclophosphamide, vincristine, and prednisone followed by tositumomab and Iodine-131\u2013tositumomab in patients with untreated low-grade follicular lymphoma: Eight-year follow-up of a multicenter phase II study","volume":"28","author":"Link","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","article-title":"Phase III randomized study of rituximab\/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab\/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: Results from the BMT CTN 0401 trial","volume":"31","author":"Vose","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.clml.2012.09.012","article-title":"A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma","volume":"12","author":"Rose","year":"2012","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1200\/JCO.2005.06.108","article-title":"Pivotal study of iodine-131\u2013labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer","volume":"23","author":"Chen","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0014-2964(67)90022-9","article-title":"Cell loss as a factor in the growth rate of human tumours","volume":"3","author":"Steel","year":"1967","journal-title":"Eur. J. Cancer"},{"key":"ref_82","first-page":"5","article-title":"131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer","volume":"21","author":"Yu","year":"2006","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"17411","DOI":"10.3390\/ijms151017411","article-title":"The biological function and clinical utilization of CD147 in human diseases: A review of the current scientific literature","volume":"15","author":"Xiong","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"9104","DOI":"10.3748\/wjg.v19.i47.9104","article-title":"131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma","volume":"19","author":"He","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_85","first-page":"657","article-title":"Hepatic Arterial Iodine-131\u2013Labeled Metuximab Injection Combined with Chemoembolization for Unresectable Hepatocellular Carcinoma: Interim Safety and Survival Data from 110 Patients","volume":"25","author":"Wu","year":"2010","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"882","DOI":"10.3348\/kjr.2016.17.6.882","article-title":"Transcatheter arterial chemoembolization plus 131I-labelled metuximab versus transcatheter arterial chemoembolization alone in intermediate\/advanced stage hepatocellular carcinoma: A systematic review and meta-analysis","volume":"17","author":"Zhu","year":"2016","journal-title":"Korean J. Radiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"dju239","DOI":"10.1093\/jnci\/dju239","article-title":"Randomized trial of [131I] metuximab in treatment of hepatocellular carcinoma after percutaneous radiofrequency ablation","volume":"106","author":"Bian","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/hep.21465","article-title":"A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation","volume":"45","author":"Xu","year":"2007","journal-title":"Hepatology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1053\/j.seminoncol.2014.07.004","article-title":"Radioimmunoconjugates for the treatment of cancer","volume":"41","author":"Rousseau","year":"2014","journal-title":"Semin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.eururo.2012.08.024","article-title":"Phase 1 Radioimmunotherapy Study with Lutetium 177\u2013labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma","volume":"64","author":"Stillebroer","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.eururo.2015.11.033","article-title":"Phase 2 study of lutetium 177\u2013labeled anti\u2013carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma","volume":"69","author":"Muselaers","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_92","first-page":"1289","article-title":"Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody","volume":"2","author":"Deb","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/pros.10029","article-title":"Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6","volume":"50","author":"DeNardo","year":"2002","journal-title":"Prostate"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2004.09.154","article-title":"Phase I trial of yttrium-90\u2014labeled anti\u2014prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer","volume":"22","author":"Milowsky","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1200\/JCO.2005.05.160","article-title":"Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer","volume":"23","author":"Bander","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-13-0231","article-title":"Phase II study of lutetium-177\u2013labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer","volume":"19","author":"Tagawa","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1002\/cncr.32072","article-title":"Phase 1\/2 study of fractionated dose lutetium-177\u2013labeled anti\u2013prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer","volume":"125","author":"Tagawa","year":"2019","journal-title":"Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00259-018-4167-0","article-title":"225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: A pilot study","volume":"46","author":"Sathekge","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/bjc.2015.202","article-title":"Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples","volume":"113","author":"Thomas","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1200\/JCO.2005.18.622","article-title":"Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results","volume":"23","author":"Liersch","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1245\/s10434-006-9328-x","article-title":"Update of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal liver metastases: Comparison of outcome to a contemporaneous control group","volume":"14","author":"Liersch","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/cncr.30390","article-title":"Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study","volume":"123","author":"Sahlmann","year":"2017","journal-title":"Cancer"},{"key":"ref_105","first-page":"465","article-title":"Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy","volume":"9","author":"Garinchesa","year":"1996","journal-title":"Int. J. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1200\/JCO.1996.14.6.1787","article-title":"J Phase I\/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer","volume":"14","author":"Welt","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.1994.12.8.1561","article-title":"Phase I\/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer","volume":"12","author":"Welt","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"ref_108","first-page":"1338","article-title":"Phase I study of anticolon cancer humanized antibody A33","volume":"9","author":"Welt","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1158\/1078-0432.CCR-04-2329","article-title":"A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: Biodistribution, pharmacokinetics, and quantitative tumor uptake","volume":"11","author":"Scott","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1158\/1078-0432.CCR-04-2330","article-title":"Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma","volume":"11","author":"Chong","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"534","DOI":"10.2967\/jnumed.113.132761","article-title":"Targeted chemoradiation in metastatic colorectal cancer: A phase I trial of 131I-huA33 with concurrent capecitabine","volume":"55","author":"Herbertson","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_112","first-page":"2229","article-title":"Initial Clinical Evaluation of Iodine-125-Labeled Chimeric 17-lA for Metastatic Colon Cancer","volume":"36","author":"Meredith","year":"1995","journal-title":"J. Nucl. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.tranon.2017.04.004","article-title":"Targeted \u03b1-particle radiation therapy of HER1-positive disseminated intraperitoneal disease: An investigation of the human anti-EGFR monoclonal antibody, panitumumab","volume":"10","author":"Milenic","year":"2017","journal-title":"Transl. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/153303460500400407","article-title":"Targeted cancer therapy using radiolabeled monoclonal antibodies","volume":"4","author":"Bethge","year":"2005","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1309\/9R6673QEC06D86Y4","article-title":"Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: An immunohistochemical study","volume":"122","author":"Lau","year":"2004","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1525-1438.2000.99510.x","article-title":"Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy","volume":"10","author":"Epenetos","year":"2000","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2005.02.5973","article-title":"Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission","volume":"24","author":"Verheijen","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1002\/ijc.22663","article-title":"Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival","volume":"120","author":"Oei","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00003072-199503000-00009","article-title":"Indium-111 OncoScint CR\/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences. Early observations","volume":"20","author":"Bohdiewicz","year":"1995","journal-title":"Clin. Nucl. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/1097-0142(19940201)73:3+<1057::AID-CNCR2820731345>3.0.CO;2-3","article-title":"Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer","volume":"73","author":"Murray","year":"1994","journal-title":"Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1006\/gyno.1996.4577","article-title":"Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: A phase I\/II study","volume":"65","author":"Alvarez","year":"1997","journal-title":"Gynecol. Oncol."},{"key":"ref_122","first-page":"2806","article-title":"A phase I study of combined modality 90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer","volume":"8","author":"Alvarez","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2967\/jnumed.120.243394","article-title":"TAG-72\u2013Targeted \u03b1-Radionuclide Therapy of Ovarian Cancer Using 225Ac-Labeled DOTAylated-huCC49 Antibody","volume":"62","author":"Minnix","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/107327481302000109","article-title":"The new golden era for radioimmunotherapy: Not just for lymphomas anymore","volume":"20","author":"Tomblyn","year":"2013","journal-title":"Cancer Control"},{"key":"ref_125","first-page":"1372","article-title":"Mucins in pancreatic cancer: Biological role, implications in carcinogenesis and applications in diagnosis and therapy","volume":"7","author":"Suh","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1158\/1078-0432.CCR-10-2579","article-title":"Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: A phase I single-dose escalation trial","volume":"17","author":"Gulec","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1200\/jco.2014.32.15_suppl.4026","article-title":"Feasibility and results of a randomized phase \u0399b study of fractionated 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies","volume":"32","author":"Picozzi","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1002\/cncr.27592","article-title":"Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial","volume":"118","author":"Ocean","year":"2012","journal-title":"Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/jso.2930470303","article-title":"Pancreatoduodenal carcinoma: A clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9","volume":"47","author":"Yamaguchi","year":"1991","journal-title":"J. Surg. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Sultana, A., Shore, S., Raraty, M.G., Vinjamuri, S., Evans, J.E., Smith, C.T., Lane, S., Chauhan, S., Bosonnet, L., and Garvey, C. (2009). Randomised Phase I\/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma. BMC Cancer, 9.","DOI":"10.1186\/1471-2407-9-66"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0165-5728(92)90029-K","article-title":"Tenascin expression in human glioma cell lines and normal tissues","volume":"36","author":"Ventimiglia","year":"1992","journal-title":"J. Neuroimmunol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/02688698808992668","article-title":"The Localisation of Radiolabeled Murine Monoclonal Antibody 81C6 and its Fab Fragment in Human Glioma Xenografts in Athymic Mice","volume":"2","author":"Colapinto","year":"1988","journal-title":"Br. J. Neurosurg."},{"key":"ref_133","first-page":"2807","article-title":"Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies","volume":"49","author":"Zalutsky","year":"1989","journal-title":"Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF01052668","article-title":"Phase I studies of treatment of malignant gliomas and neoplastic meningitis with131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab\u2032)2-a preliminary report","volume":"24","author":"Bigner","year":"1995","journal-title":"J. Neuro-Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1200\/JCO.2000.18.22.3862","article-title":"Phase I trial results of iodine-131\u2013labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas","volume":"18","author":"Cokgor","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.2002.20.5.1389","article-title":"Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas","volume":"20","author":"Reardon","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_137","first-page":"1042","article-title":"Dosimetry and radiographic analysis of 131I-labeled anti\u2212 tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: A Phase II study","volume":"46","author":"Akabani","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1215\/15228517-2007-053","article-title":"A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost","volume":"10","author":"Reardon","year":"2008","journal-title":"Neuro Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3171\/2014.12.JNS142168","article-title":"Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy","volume":"123","author":"Reulen","year":"2015","journal-title":"J. Neurosurg."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF02789213","article-title":"Glioblastoma therapy by direct intralesional administration of I-131 radioiodine labeled antitenascin antibodies","volume":"24","author":"Riva","year":"1994","journal-title":"Cell Biophys."},{"key":"ref_141","first-page":"2733","article-title":"Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: A six-year clinical experience","volume":"80","author":"Riva","year":"1997","journal-title":"Cancer Interdiscip. Int. J. Am. Cancer Soc."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/028418699431438","article-title":"131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma: Phase I and II study","volume":"38","author":"Riva","year":"1999","journal-title":"Acta Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/01.COC.0000041009.06780.E5","article-title":"Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: Ten-year synopsis of a novel treatment","volume":"25","author":"Emrich","year":"2002","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3171\/2010.2.JNS091211","article-title":"A phase II study of anti\u2013epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme","volume":"113","author":"Li","year":"2010","journal-title":"J. Neurosurg."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4161\/cbt.7.3.5414","article-title":"Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma","volume":"7","author":"Casaco","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3389\/fphar.2019.00772","article-title":"Potential for nuclear medicine therapy for glioblastoma treatment","volume":"10","author":"Bailly","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_148","first-page":"29","article-title":"Possible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia","volume":"18","author":"Jovanovic","year":"2014","journal-title":"Contemp. Oncol."},{"key":"ref_149","first-page":"2000","article-title":"Radioimmunotherapy of non-Hodgkin\u2019s lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): Do tumor targeting and dosimetry predict therapeutic response?","volume":"44","author":"Sharkey","year":"2003","journal-title":"J. Nucl. Med."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1158\/1078-0432.CCR-05-0172","article-title":"Dose-fractionated radioimmunotherapy in non-Hodgkin\u2019s lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab","volume":"11","author":"Hindorf","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1200\/JCO.2009.27.7863","article-title":"High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: Results of a multicenter, phase I\/II study in non-Hodgkin\u2019s lymphoma","volume":"28","author":"Morschhauser","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V120.21.906.906","article-title":"Consolidation anti-CD22 fractionated radioimmunotherapy with 90y-epratuzumab tetraxetan following R-CHOP in elderly DLBCL patients: A lysa phase II prospective trial","volume":"120","author":"Pallardy","year":"2012","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(16)30168-5","article-title":"Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: A prospective, single group, phase 2 trial","volume":"4","author":"Pallardy","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_154","first-page":"672","article-title":"227Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed\/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study","volume":"36","author":"Bates","year":"2021","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/172460088700200107","article-title":"Treatment of a patient with B cell lymphoma by 1-131 LYM-1 monoclonal antibodies","volume":"2","author":"DeNardo","year":"1987","journal-title":"Int. J. Biol. Markers"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.1998.16.10.3246","article-title":"Maximum-tolerated dose, toxicity, and efficacy of (131) I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin\u2019s lymphoma","volume":"16","author":"DeNardo","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_157","first-page":"3647","article-title":"A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin\u2019s lymphoma","volume":"20","author":"Shen","year":"2000","journal-title":"Anticancer. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1200\/JCO.1993.11.10.2021","article-title":"Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin\u2019s lymphoma","volume":"11","author":"Czuczman","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.1990.8.5.792","article-title":"A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin\u2019s lymphoma: Effects of tumor burden and antigen expression","volume":"8","author":"Scheinberg","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.1989.7.8.1027","article-title":"Treatment of refractory non-Hodgkin\u2019s lymphoma with radiolabeled MB-1 (anti-CD37) antibody","volume":"7","author":"Press","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.1992.10.11.1696","article-title":"Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma","volume":"10","author":"Kaminski","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1182\/bloodadvances.2020002583","article-title":"Phase 1\/2a study of 177Lu-lilotomab satetraxetan in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"4","author":"Kolstad","year":"2020","journal-title":"Blood Adv."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1158\/1538-7445.AM2016-3123","article-title":"Aberrant expression of CD33 is associated with poor prognosis in patients with multiple myeloma and tumor progression","volume":"76","author":"Lee","year":"2016","journal-title":"Cancer Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1038\/sj.leu.2403948","article-title":"CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target","volume":"19","author":"Robillard","year":"2005","journal-title":"Leukemia"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"S329","DOI":"10.1016\/j.clml.2017.07.141","article-title":"Trial in progress: Phase I study of actinium-225 (225Ac)-lintuzumab in patients with refractory multiple myeloma","volume":"17","author":"Levy","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_166","first-page":"13","article-title":"CD38 antibodies in multiple myeloma: Back to the future","volume":"131","author":"Richardson","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_167","first-page":"1247","article-title":"The \u03b1-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model","volume":"134","author":"Comstock","year":"2019","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1607673","DOI":"10.1080\/2162402X.2019.1607673","article-title":"Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors","volume":"8","author":"Dawicki","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1365-2141.2008.07024.x","article-title":"Anti-CD20 monoclonal antibody therapy in multiple myeloma","volume":"141","author":"Kapoor","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/bmt.2017.164","article-title":"A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma","volume":"52","author":"Dispenzieri","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/j.bbmt.2014.11.304","article-title":"A phase II, safety and efficacy study of fixed dose radioimmunotherapy (Zevalin, yttrium-90 ibritumomab tiuxetan) for patients with incomplete response to chemotherapy prior to autologous stem cell transplant (ASCT) for multiple myeloma","volume":"21","author":"Gao","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_172","first-page":"2041","article-title":"The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy","volume":"110","author":"Yang","year":"2007","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s13277-012-0362-y","article-title":"Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients","volume":"33","author":"Rousseau","year":"2012","journal-title":"Tumor Biol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1146\/annurev.iy.07.040189.002011","article-title":"The leukocyte common antigen family","volume":"7","author":"Thomas","year":"1989","journal-title":"Annu. Rev. Immunol."},{"key":"ref_175","first-page":"1237","article-title":"Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome","volume":"94","author":"Matthews","year":"1999","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/sj.bmt.1705182","article-title":"Radioimmunoconjugates in acute leukemia treatment: The future is radiant","volume":"36","author":"Kotzerke","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood-2005-06-2317","article-title":"131I\u2013anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission","volume":"107","author":"Pagel","year":"2006","journal-title":"Blood"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1309\/E36008Y2H08Q1AYY","article-title":"CD33 detection by immunohistochemistry in paraffin-embedded tissues: A new antibody shows excellent specificity and sensitivity for cells of myelomonocytic lineage","volume":"129","author":"Hoyer","year":"2008","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/blood.V83.7.1760.1760","article-title":"A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity","volume":"83","author":"Caron","year":"1994","journal-title":"Blood"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.bmt.1704201","article-title":"Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias","volume":"32","author":"Burke","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Mastren, T. (2021). Targeted Alpha Therapy. Rare Earth Elements and Actinides: Progress in Computational Science Applications, ACS Publications.","DOI":"10.1021\/bk-2021-1388.ch013"},{"key":"ref_182","first-page":"1233","article-title":"Targeted \u03b1 particle immunotherapy for myeloid leukemia. Blood","volume":"100","author":"Jurcic","year":"2002","journal-title":"J. Am. Soc. Hematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/6\/1454\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:35:19Z","timestamp":1760135719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/6\/1454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":182,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["cancers14061454"],"URL":"https:\/\/doi.org\/10.3390\/cancers14061454","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]}}}